Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Skin cancer is rare in black patients. The clinical course and pathology of 58 cases are presented and reviewed. These include 38 squamous cell carcinomas, 13 malignant melanomas, and 7 basal cell carcinomas. Sixty-one percent of the squamous cell carcinomas developed in unexposed areas, with sunlight exposure apparently not being an important etiologic factor. Forty-one percent of the squamous cell carcinomas had predisposing factors such as burn scars or chronic infection. Squamous cell carcinoma in black patients is an aggressive disease, with 29% developing regional lymph node metastasis, and a mortality of 29%. Malignant melanomas occurred most frequently on the plantar surface of the foot (76%). Melanoma is also a virulent tumor in black patients, with 11 of 13 patients developing lymph node metastasis and only 2 patients surviving. Skin cancer in black patients presents a very different clinical picture than that seen in white patients. It is important that these factors be considered when planning therapy.
 ...
PMID:Skin cancer in black patients. 111 31

Melanoma currently offers challenges to the medical profession. Opportunities for early detection, development of rational immunotherapy, and gains in curability are unparalled because of the recently defined aspects of early recognition, its cutaneous location, the long periods of superficial lateral growth, the increasing incidence, and the many fascinating immunologic aspects of melanoma.
 ...
PMID:Changinc concepts in malignant melanoma. 111 66

KCl extracts of Melanoma 14, a human melanoma cell line grown in chemically defined serum-free medium, inhibited leukocyte migration in 19/36 (53%) patients with malignant melanoma. Only 4/23 (17%) controls with non-melanoma malignancies and 4/25 (14%) normal subjects with no history of cancer were similarly inhibited. Only 2/27 melanoma patients tested against KCl extracts of normal muscle tissue excised from the donor of Melanoma 14 were significantly inhibited. Patients with Stage I (localized) melanoma and patients with Stage III (generalized) melanoma reacted with roughly equal frequency but the number of patients in each group was too small for meaningful statistical analysis. Leukocytes from the donor of Melanoma 14 were tested in a completely autologous system against extracts of Melanoma 14 tissue culture cells and extracts of autologous muscle and were specifically inhibited by the Melanoma 14 tissue culture extract (Migration Index = 0.67) but not by the extract of normal muscle (Migration Index = 0.96). Only 7/32 (22%) melanoma patients were significantly inhibited by an extract of non-melanoma tumor. These results suggest that melanoma-associated antigens are present in soluble extracts of this tumor line. Such extracts could provide a continuing source of standard melanoma-associated antigens for purification and chemical characterization and for diagnostic and prognostic tests in patients with malignant melanoma.
 ...
PMID:Inhibition of leukocyte migration in agarose by KCl extracts of human melanoma cell line grown in serum-free medium. 120 72

Immunization studies indicate that formalinized tumour cells retain at least part of their gross membrane structure and antigenicity; they are relatively easy to prepare and store well over a period of months. We have used formalinized tumour cells as antigen in the leucocyte migration inhibition test. Leucocyte migration inhibition occurred in leucocytes from thirty-eight out of sixty-nine malignant melanoma patients and from fifty-five out of eight-one breast cancer patients when in contact with formalinized tumour cells of a histologically similar type. Melanoma patients' and breast cancer patients' leucocytes were infrequently inhibited on contact with cells from histologically dissimilar human tumours and from xenogeneic mouse melanomas. Other advantages of formalinized cells over antigens prepared by homogenizing tumour tissue include a greater degree of inhibition and the ability to demonstrate a dose-response relationship between the ratio of leucocytes:tumour cells and the migration index.
 ...
PMID:Formalinized tumour cells in the leucocyte migration inhibition test. 121 13

To test the hypothesis that radiosensitization by combined mild hyperthermia and chloroquine may be increased by the presence of melanin in treated cells, Cloudman melanotic mouse melanoma S91/6 cells, and the amelanotic S91/amel cells were incubated during a 3 h post-irradiation period with 0.03 mM chloroquine at 41 degrees C. A considerable increase in radiation lethality was observed (radiation potentiation factor > 1.6) in both cases. Addition of 0.1 mM isobutyl-methyl xanthine (IBMX), a promoter of melanin synthesis, to the growth medium of S91/6 cells 10 days before irradiation, did not further increase the lethality of radiation followed by combined heat and chloroquine treatment. Under these conditions, toxicity to unirradiated cells was slight. On the other hand, 10 microM chloroquine showed similar toxicity to unirradiated B-16 mouse melanoma cells, but did not increase radiation lethality. Factors other than melanin content therefore play a role in the potentiation of radiation lethality by mild hyperthermia and chloroquine.
Melanoma Res 1992 Dec
PMID:Potentiation of radiation lethality in mouse melanoma cells by mild hyperthermia and chloroquine. 128 43

The aim of this work was to develop a computer program (CANEST) to estimate the risk of cancer in patient populations and to use this program to investigate cancer risk associated with several dermatological disorders. Patients seen at the dermatology departments at the Karolinska Hospital and South Hospital were used for the study of chronic urticaria, condylomata acuminata, basal cell carcinoma, lichen planus and positive patch tests. The national Swedish In-Patient Register was used to find all patients hospitalized for dermatomyositis or polymyositis since 1964. From eleven large dermatological centers in Sweden, details of close to 5,000 PUVA-treated patients were obtained for study. The computer program CANEST was developed and used to calculate the expected number of malignant tumors in these patient populations, based on incidence data from the Swedish Cancer Register for the years 1958-1987. By matching the patients' records with the Cancer Register the actual number of cancers was obtained. Of 1,155 patients with chronic urticaria, a malignancy was diagnosed in 36, while the expected number was 41: clearly there is therefore no association between chronic urticaria and malignancy. In 3,260 patients with condylomata acuminata there was no increased risk of cancer in situ of the cervix (relative risk = 1.5; 95% confidence interval 0.9 to 2.5) and the number of genitourinary cancers in males was almost three times higher than expected (2.6; 1.2 to 5.0). These results indicate that the risk of developing cervical carcinoma in situ is less than previously thought, but the implications of the increase in genitourinary tumors in males are uncertain. Patients with basal cell carcinoma had an increased risk of malignancy in general. Melanoma risk was seven times greater in males (6.6; 3.0 to 12.5) after the basal cell carcinoma diagnosis. Risks of squamous cell carcinoma of the skin, lung cancer, thyroid cancer and cancer of the uterine cervix were also increased. No increased risk of cutaneous malignancy was found in 2,071 patients with lichen planus, but for oral cancer it was six times greater in males (5.9; 2.5 to 11.4). A slight general increase in malignancy risk was found in 2,183 males (1.3; 1.1 to 1.5) with positive patch tests, but not in 3,675 females. When individual sites were analyzed, cancers of the lung, larynx, uterine cervix and prostate were significantly increased. The implications of this are uncertain, but might indicate a common failure of the immune system which might predispose for both conditions, or be a marker of certain occupational exposure.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Skin disease and malignancy. An epidemiological study. 128 38

Substituted phenolic compounds were previously shown to exhibit cytotoxicity towards epithelial cells in the presence of the enzyme tyrosinase as a result of the formation of their quinone products. Seventeen of these compounds were tested for cytotoxic properties towards three different melanoma cell lines. The compounds were split into four groups of phenol derivatives, A; alkoxyethers, including 4-hydroxyanisole (4HA), B; oxyethers derivatized at the acyl side chain, C; oxyethers derivatized at the phenol, and D; acyl thioethers. Toxicity was determined by total cell counts after 3 days exposure to the compounds. Large reductions in cell numbers were observed with 4HA (the methoxy-), ethoxy-, propoxy and iso-butoxyethers of group A and the methyl- and propyl thioethers of phenol of group D. Derivatization of the ethoxy- and propoxy side chains (group B) did not seem to increase the cytotoxic effects, as determined by cell counts. Compounds of group C, which need intracellular esterase activity to release the phenols, showed moderate toxicities. Toxicity of certain compounds was confirmed by LDH release into the culture medium and by increased trypan blue uptake of cells exposed to the compounds. Flow cytometric investigations of cells after exposure for 24 h revealed that most compounds caused an increase in the proportion of cells in G1 phase. A complete accumulation of cells in S-phase was observed after exposure to 4-ethoxyphenol. Inhibition of DNA synthesis was also shown by inhibition of bromodeoxyuridine incorporation. The results presented show that phenolic compounds exhibit cytotoxic properties towards melanoma cells some of which may be mediated by tyrosinase activity. Toxicity of the compounds was shown to be exerted during DNA replication but their toxic action may also be due to membrane damage and inhibition of cell metabolism.
Melanoma Res 1992 Dec
PMID:Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells. 129 81

Supernatants of a human malignant cell line established from a CNS metastasis, contained several proteins with putative growth regulating functions. BioGel P-10 gel filtration chromatography, reverse phase HPLC purification, and amino-terminal sequencing of purified peptides resulted in characterization of beta 2-microglobulin (beta 2M, 10 kD), ubiquitin (6 kD), and tissue inhibitor of metalloproteinases 2 (TIMP-2, 21 kD). In addition, CNBr cleavage and purification of resulting peptides revealed diazepam binding inhibitor (DBI, 8 kD) and melanoma inhibiting activity (MIA, 11 kD). The secretion of beta 2M as part of the HLA-class I complex may be related to impaired autologous anti-tumour immune function; ubiquitin may play a role in activation or deactivation of extracellular proteins or cell-cell interactions. As HTZ-19 cells respond in a dose-dependent manner to midozolam, DBI may interfere with growth regulation mediated by diazepam receptor sites. In a collagenolytic assay, TIMP-2 interfered with metalloproteinase functions, which are required for degradation of collagen type IV and organotopic metastasis. MIA is clearly associated with a proliferation inhibiting effect on HTZ-19 cells. In conclusion, although this tumour shows a degree of progression, several proteins with putative functions at different cellular levels were identified, related to proliferation as well as to the type of metastasis.
Melanoma Res 1992 Dec
PMID:Purification and analysis of growth regulating proteins secreted by a human melanoma cell line. 129 82

R24 is a mouse IgG3 monoclonal antibody that reacts with the ganglioside GD3 expressed by melanoma cells and other cells of neuroectodermal origin (e.g. adrenal medulla). Antitumour activity of R24 was demonstrated in initial phase I and pilot trials, but treatment was limited by urticaria at cumulative doses of 400 mg/m2. A trial exploring intensification of the dose of R24 was conducted in eight patients. Planned doses of R24 antibody were 800 and 1200 mg/m2 over 6-8 days by continuous i.v. infusion. All patients received concomitant therapy with hydroxyzine hydrochloride and cimetidine to minimize urticaria. One patient developed anaphylaxis, after which no further therapy was given. All patients developed peripheral blood lymphopenia and marked decreases in serum complement values during treatment, suggesting depletion of two possible effector mechanisms of the antitumour effects of R24. A vascular leak syndrome, manifested by weight gain, oedema and hypotension, was evident in seven patients during the initial 24-36 h of treatment. Serum sickness syndrome was observed in six of seven evaluable patients between days 5 and 8, coincident with the onset of the human anti-globulin response to R24. One patient given 1200 mg/m2 had a minor response (38% reduction in pelvic nodes) lasting 12 months. There was no detectable increase (by immunohistochemical staining) in deposition of R24 within tumour sites at doses used in this trial compared to that observed at doses of 240 and 400 mg/m2. The maximum tolerated dose was 800 mg/m2. Dose-limiting toxicity was manifest as reversible hypertension with end-organ symptoms (chest pain or visual field defects) in patients treated with a dose of 1200 mg/m2.(ABSTRACT TRUNCATED AT 250 WORDS)
Melanoma Res 1992 Dec
PMID:Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma. 129 83


Melanoma Res 1992 Dec
PMID:The relationship of tumour antigens to normal proteins, with special reference to albumin-like melanoma antigens. 129 84


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>